Heilongjiang ZBD Pharmaceutical
Market Cap
CN¥11.5b
Last Updated
2021/04/17 09:14 UTC
Data Sources
Company Financials
Executive Summary
Heilongjiang ZBD Pharmaceutical Co., Ltd. More Details
Risk Analysis
Snowflake Analysis
Mediocre balance sheet unattractive dividend payer.
Share Price & News
How has Heilongjiang ZBD Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 603567 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 603567's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
-2.3%
603567
-2.8%
CN Pharmaceuticals
-0.8%
CN Market
1 Year Return
8.7%
603567
10.4%
CN Pharmaceuticals
25.0%
CN Market
Return vs Industry: 603567 underperformed the CN Pharmaceuticals industry which returned 10.4% over the past year.
Return vs Market: 603567 underperformed the CN Market which returned 25% over the past year.
Shareholder returns
| 603567 | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.3% | -2.8% | -0.8% |
| 30 Day | 5.2% | 1.0% | -0.08% |
| 90 Day | 28.8% | -5.1% | -5.3% |
| 1 Year | 10.7%8.7% | 11.5%10.4% | 27.0%25.0% |
| 3 Year | 7.3%2.7% | 25.2%20.8% | 29.1%22.8% |
| 5 Year | -25.2%-29.9% | 46.5%38.7% | 30.5%21.7% |
Long-Term Price Volatility Vs. Market
How volatile is Heilongjiang ZBD Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Heilongjiang ZBD Pharmaceutical undervalued compared to its fair value and its price relative to the market?
36.79x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 603567 (CN¥13.46) is trading above our estimate of fair value (CN¥4.33)
Significantly Below Fair Value: 603567 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 603567 is poor value based on its PE Ratio (36.8x) compared to the CN Pharmaceuticals industry average (31.9x).
PE vs Market: 603567 is poor value based on its PE Ratio (36.8x) compared to the CN market (33.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 603567's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 603567 is good value based on its PB Ratio (2.2x) compared to the CN Pharmaceuticals industry average (2.7x).
Future Growth
How is Heilongjiang ZBD Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
24.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Heilongjiang ZBD Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Heilongjiang ZBD Pharmaceutical performed over the past 5 years?
-9.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 603567 has a large one-off gain of CN¥117.6M impacting its September 30 2020 financial results.
Growing Profit Margin: 603567's current net profit margins (10.5%) are lower than last year (14.6%).
Past Earnings Growth Analysis
Earnings Trend: 603567's earnings have declined by 9.5% per year over the past 5 years.
Accelerating Growth: 603567's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603567 had negative earnings growth (-27.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.3%).
Return on Equity
High ROE: 603567's Return on Equity (5.8%) is considered low.
Financial Health
How is Heilongjiang ZBD Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 603567's short term assets (CN¥5.9B) exceed its short term liabilities (CN¥1.3B).
Long Term Liabilities: 603567's short term assets (CN¥5.9B) exceed its long term liabilities (CN¥2.8B).
Debt to Equity History and Analysis
Debt Level: 603567's debt to equity ratio (58.4%) is considered high.
Reducing Debt: 603567's debt to equity ratio has increased from 19.1% to 58.4% over the past 5 years.
Debt Coverage: 603567's debt is not well covered by operating cash flow (2.2%).
Interest Coverage: 603567 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Heilongjiang ZBD Pharmaceutical current dividend yield, its reliability and sustainability?
1.61%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 603567's dividend (1.61%) is higher than the bottom 25% of dividend payers in the CN market (0.44%).
High Dividend: 603567's dividend (1.61%) is low compared to the top 25% of dividend payers in the CN market (1.79%).
Stability and Growth of Payments
Stable Dividend: 603567 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 603567 has only been paying a dividend for 5 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (59.3%), 603567's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CN¥624k
CEO Compensation
CEO
Tong Hua Fang
no data
Tenure
CN¥623,700
Compensation
Mr. Tong Hua Fang serves as the Chairman and General Manager at Heilongjiang ZBD Pharmaceutical Co., Ltd.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Heilongjiang ZBD Pharmaceutical Co., Ltd.
- Ticker: 603567
- Exchange: SHSE
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥11.459b
- Shares outstanding: 849.16m
- Website: https://www.zbdzy.com
Number of Employees
Location
- Heilongjiang ZBD Pharmaceutical Co., Ltd.
- No. 72 Hongxing Street
- Hulin
- China
Listings
Biography
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthope...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/17 09:14 |
| End of Day Share Price | 2021/04/16 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.